All In Biotech

Drug Trial Radar · NCT06872125

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients With Dravet Syndrome

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 170 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

170

Planned (sponsor's estimate)

Start

Jun 4, 2025

Primary completion

Mar 2027

Study completion Oct 2028

Sponsor

Lead sponsor
Stoke Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Mar 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.

Conditions

  • Dravet Syndrome

Interventions

  • zorevunersenDrug

    Treatment Period 1: Zorevunersen group will receive study drug by intrathecal (IT) administration on Day 1 (after the 8-week Baseline Period), Day 57 (Week 8), Day 169 (Week 24), and Day 281 (Week 40) at a dose level of 70 mg on Day 1 and Day 57, and 45 mg on Day 169 and Day 281. Treatment Period 2: Group assigned to zorevunersen in Treatment Period 1 will receive 45 mg of zorevunersen on Day 393 (Week 56), Day 477 (Week 68), and Day 589 (Week 84).

  • Sham ComparatorOther

    Treatment Period 1: Sham group will not have drug administered. Sham group will have a procedure intended to mimic the drug administration. Treatment Period 2: Group assigned to sham in Treatment Period 1 will receive 70 mg of zorevunersen on Day 393 (Week 56) and on Day 477 (Week 68), and 45 mg of zorevunersen Day 589 (Week 84).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Measurement of Seizure ChangeTime frame: Week 28

Locations

61 sites in 8 countries. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • Cedars Sinai Medical Center

    Los Angeles, California

  • Children's Hospital of Orange County

    Orange, California

  • USCF Medical Center

    San Francisco, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Nemours Children's Health

    Jacksonville, Florida

  • Nicklaus Children's Hospital

    Miami, Florida

  • Advent Health Neuroscience Research Institute

    Orlando, Florida

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Boston Children's Hospital

    Boston, Massachusetts

  • CS Mott Children's Hospital

    Ann Arbor, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • NYU Langone Health

    New York, New York

  • Weill Cornell Medicine

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Duke University Health System

    Durham, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • Nationwide Children's Hospital

    Columbus, Ohio

  • Oregon Health & Science University (OHSU)

    Portland, Oregon

  • LeBonheur Children's Hospital

    Memphis, Tennessee

  • Cook Children's Medical Center

    Fort Worth, Texas

  • Texas Children's Hospital

    Houston, Texas

  • University of Utah Primary Children's Hospital

    Salt Lake City, Utah

  • UVA Health

    Charlottesville, Virginia

  • Peking University First Hospital

    Beijing, China

  • The Second Affiliated Hospital of Guangzhou Medical university

    Guangzhou, China

  • Wuhan Children's Hospital

    Wuhan, China

  • Hôpital de la Timone

    Marseille, France

  • Hôpital Necker - Enfants Malades

    Paris, France

  • Hôpital Robert Debré - Paris

    Paris, France

  • Charité - Campus Virchow-Klinikum

    Berlin, Germany

  • Universitaetsklinikum Bonn AoeR

    Bonn, Germany

  • Universitaetsklinikum Frankfurt Goethe-Universitaet

    Frankfurt, Germany

  • Universitaetsklinikum Freiburg

    Friedberg, Germany

  • Universitaetsklinikum Heidelberg

    Heidelberg, Germany

  • Integriertes Sozialpaediatrisches Zentrum

    München, Germany

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.